Details
Stereochemistry | ACHIRAL |
Molecular Formula | C21H26O3 |
Molecular Weight | 326.4293 |
Optical Activity | UNSPECIFIED |
Defined Stereocenters | 2 / 2 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
CC(C)(C)[C@H]1CC[C@H](CC2=C(O)C(=O)C3=CC=CC=C3C2=O)CC1
InChI
InChIKey=KLLIVCPQDTYMLC-HDJSIYSDSA-N
InChI=1S/C21H26O3/c1-21(2,3)14-10-8-13(9-11-14)12-17-18(22)15-6-4-5-7-16(15)19(23)20(17)24/h4-7,13-14,24H,8-12H2,1-3H3/t13-,14-
Molecular Formula | C21H26O3 |
Molecular Weight | 326.4293 |
Charge | 0 |
Count |
|
Stereochemistry | ABSOLUTE |
Additional Stereochemistry | No |
Defined Stereocenters | 2 / 2 |
E/Z Centers | 0 |
Optical Activity | UNSPECIFIED |
Buparvaquone is a second-generation hydroxynaphtaquinone with novel features that make it an effective compound for the therapy and prophylaxis of all forms of theileriosis. It has shown promising activities against Leishmania spp. and Neospora caninum infection. In combination with arteether it is effective against Babesia equi. Buparvaquone directly inhibits the respiration of Theileria parasites. Due to the inhibiting effects of theileriosis on the immune system, vaccination should be delayed until the animal has recovered from theileriosis. Localised, painless, oedematous swelling may occasionally be seen at the injection site.
Originator
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: Cytochrome bc1 complex (Leishmania) Sources: https://www.ncbi.nlm.nih.gov/pubmed/27297476 |
0.061 µM [IC50] | ||
Target ID: GO:0045333 |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Curative | Butalex Approved UseIndicated for the treatment of tick-transmitted theileriosis caused by the intracellular protozoan parasites Theileria parva (East Coast fever, Corridor disease, Zimbabwean theileriosis) and T. annulata (tropical theileriosis) in cattle. |
|||
Primary | Butalex Approved UseUnknown |
|||
Curative | Butalex Approved UseUnknown |
PubMed
Title | Date | PubMed |
---|---|---|
The activity of hydroxynaphthoquinones against Leishmania donovani. | 1992 Dec |
|
In-vivo therapeutic efficacy trial with artemisinin derivative, buparvaquone and imidocarb dipropionate against Babesia equi infection in donkeys. | 2003 Nov |
|
Clinical, haematological and therapeutic studies on tropical theileriosis in water buffaloes (Bubalus bubalis) in Egypt. | 2007 May 31 |
|
Effectiveness of liposomal buparvaquone in an experimental hamster model of Leishmania (L.) infantum chagasi. | 2012 Mar |
Patents
Sample Use Guides
In Vivo Use Guide
Sources: http://www.fivetanimalhealth.com/products/butalex
Cattle: A single dose of 1 ml per 20 kg body weight. (2.5 mg buparvaquone/kg body weight). In severe and advanced cases, a second treatment may be required at 48-72 hrs after the initial injection at the same dose rate.
Route of Administration:
Intramuscular
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/25941626
In 4-day proliferation assays, buparvaquone efficiently inhibited Neospora caninum tachyzoite replication (IC50 = 4.9 nM; IC100 = 100 nM).
Substance Class |
Chemical
Created
by
admin
on
Edited
Sat Dec 16 17:04:49 GMT 2023
by
admin
on
Sat Dec 16 17:04:49 GMT 2023
|
Record UNII |
0354RT7LG4
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Code | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
WHO-VATC |
QP51AX22
Created by
admin on Sat Dec 16 17:04:49 GMT 2023 , Edited by admin on Sat Dec 16 17:04:49 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
C73276
Created by
admin on Sat Dec 16 17:04:49 GMT 2023 , Edited by admin on Sat Dec 16 17:04:49 GMT 2023
|
PRIMARY | |||
|
DTXSID4057849
Created by
admin on Sat Dec 16 17:04:49 GMT 2023 , Edited by admin on Sat Dec 16 17:04:49 GMT 2023
|
PRIMARY | |||
|
5549
Created by
admin on Sat Dec 16 17:04:49 GMT 2023 , Edited by admin on Sat Dec 16 17:04:49 GMT 2023
|
PRIMARY | |||
|
100000088465
Created by
admin on Sat Dec 16 17:04:49 GMT 2023 , Edited by admin on Sat Dec 16 17:04:49 GMT 2023
|
PRIMARY | |||
|
SUB05980MIG
Created by
admin on Sat Dec 16 17:04:49 GMT 2023 , Edited by admin on Sat Dec 16 17:04:49 GMT 2023
|
PRIMARY | |||
|
88426-33-9
Created by
admin on Sat Dec 16 17:04:49 GMT 2023 , Edited by admin on Sat Dec 16 17:04:49 GMT 2023
|
PRIMARY | |||
|
m2765
Created by
admin on Sat Dec 16 17:04:49 GMT 2023 , Edited by admin on Sat Dec 16 17:04:49 GMT 2023
|
PRIMARY | Merck Index | ||
|
0354RT7LG4
Created by
admin on Sat Dec 16 17:04:49 GMT 2023 , Edited by admin on Sat Dec 16 17:04:49 GMT 2023
|
PRIMARY | |||
|
CHEMBL292009
Created by
admin on Sat Dec 16 17:04:49 GMT 2023 , Edited by admin on Sat Dec 16 17:04:49 GMT 2023
|
PRIMARY | |||
|
C046326
Created by
admin on Sat Dec 16 17:04:49 GMT 2023 , Edited by admin on Sat Dec 16 17:04:49 GMT 2023
|
PRIMARY | |||
|
Buparvaquone
Created by
admin on Sat Dec 16 17:04:49 GMT 2023 , Edited by admin on Sat Dec 16 17:04:49 GMT 2023
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |